Prospective Study of Clinical Phenotypes in Neuropsychiatric Systemic Lupus Erythematosus; Multidisciplinary Approach to Diagnosis and Therapy
Authors:
- Elisabeth J.M. ZirkzeeEZElisabeth J.M. Zirkzee
- Gerda M. Steup-BeekmanGSGerda M. Steup-Beekman
- Roos C. van der MastRMRoos C. van der Mast
- Eduard L.E.M. BollenEBEduard L.E.M. Bollen
- NIC J.A. van der WeeNWNIC J.A. van der Wee
- Esther BaptistEBEsther Baptist
- Thomas M. SleeTSThomas M. Slee
- Menno V. HuismanMHMenno V. Huisman
- Huub A.M. MiddelkoopHMHuub A.M. Middelkoop
- Jasper LuyendijkJLJasper Luyendijk
- Mark A. van BuchemMBMark A. van Buchem
- Tom W.J. HuizingaTHTom W.J. Huizinga
- 15 September 2012
- journal article
- research article
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 39 (11) , 2118-2126
Abstract
Objective. To describe clinical phenotypes in neuropsychiatric systemic lupus erythematosus (NPSLE). Methods. Data were prospectively collected in the Leiden NPSLE referral clinic, where patients suspected of having NPSLE are assessed in a standardized multidisciplinary manner. In consensus meetings, all medical specialists agreed on therapeutic strategy based on the suspected pathogenetic mechanism of NPSLE in the individual patient. An algorithm illustrates the process of decision-making during the consensus meeting. Clinical phenotypes are described, classified by pathogenetic mechanism. Results. One hundred consecutive patients were evaluated, of whom 71 had SLE (29 patients did not fulfill ≥ 4 American College of Rheumatology criteria) and 46 had NPSLE. Primary NPSLE was diagnosed in 38 patients (53%) and could be differentiated in 21 patients (55%) with inflammatory NPSLE who were advised on immunosuppressive therapy, 12 patients (32%) with ischemic NPSLE who were advised on anticoagulant therapy, and 5 patients (13%) with undefined NPSLE who were advised symptomatic treatment only. Cognitive dysfunction and higher level of disease activity were associated with inflammatory NPSLE. Although presence of immunoglobulin G anticardiolipin antibodies and abnormalities on magnetic resonance imaging (MRI) were associated with ischemic NPSLE, abnormalities on MRI lacked specificity to distinguish phenotypes. A history of renal disease and use of corticosteroids were associated with secondary NPSLE. Conclusion. We describe multidisciplinary consensus as a standard for diagnosing and defining phenotypes in NPSLE. These phenotypes show specific characteristics, which can be used to support diagnosis and guide therapeutic decisions. Clinical phenotyping and selection of patients becomes increasingly important when advances in experimental science lead to new targets for therapy in NPSLE.Keywords
This publication has 41 references indexed in Scilit:
- Neurotoxic lupus autoantibodies alter brain function through two distinct mechanismsProceedings of the National Academy of Sciences, 2010
- Anti-α-Internexin Autoantibody from Neuropsychiatric Lupus Induce Cognitive Damage via Inhibiting Axonal Elongation and Promote Neuron ApoptosisPLOS ONE, 2010
- Pathogenesis of neuropsychiatric systemic lupus erythematosus and potential biomarkersModern Rheumatology, 2009
- Neuropsychiatric Involvement in Systemic Lupus Erythematosus:Current Therapeutic ApproachCurrent Pharmaceutical Design, 2008
- Management of neuropsychiatric lupusBest Practice & Research Clinical Rheumatology, 2005
- ACR classification criteria for systemic lupus erythematosus: limitations and revisions to neuropsychiatric variablesLupus, 2004
- The ACR nomenclature for CNS lupus revisitedLupus, 2003
- Neuropsychiatric syndromes in lupusNeurology, 2002
- The prevalence of neuropsychiatric syndromes in systemic lupus erythematosusNeurology, 2001
- The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromesArthritis & Rheumatism, 1999